Concepedia

Farshid Dayyani

FD

Statistics

Publications

51

Citations

5.1K

H-Index

29

Active since

2000

Affiliations

University of California, Irvine(Current)

The University of Texas MD Anderson Cancer Center

Massachusetts General Hospital

Ludwig-Maximilians-Universität München

Natera (United States)

Farshid Dayyani is an author at University of California, Irvine specializing in medicine, oncology, and radiation oncology.

ORCID

Top concepts

Publications per year

2000–2025

51

Publications

51

The Proinflammatory CD14+CD16+DR++ Monocytes Are a Major Source of TNF

Kai-Uwe Belge, Farshid Dayyani, Alexia Horelt et al. · The Journal of Immunology · 2002 · 873 citations · Full text

, , +17

Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma

Andrew X. Zhu, Alexander R. Abbas, Marina Ruiz de Galarreta et al. · Nature Medicine · 2022 · 580 citations

, , +9

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial

Sun Young Rha, Do‐Youn Oh, Patricio Yañez et al. · The Lancet Oncology · 2023 · 521 citations

, , +8

Resistance to BRAF Inhibition in BRAF-Mutant Colon Cancer Can Be Overcome with PI3K Inhibition or Demethylating Agents

Muling Mao, Feng Tian, John M. Mariadason et al. · Clinical Cancer Research · 2012 · 297 citations

Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

B. Sangro, Stephen L. Chan, Robin Kate Kelley et al. · Annals of Oncology · 2024 · 254 citations · Full text

1–5 of 51